These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21990410)

  • 1. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
    Groen HJ; Sietsma H; Vincent A; Hochstenbag MM; van Putten JW; van den Berg A; Dalesio O; Biesma B; Smit HJ; Termeer A; Hiltermann TJ; van den Borne BE; Schramel FM
    J Clin Oncol; 2011 Nov; 29(32):4320-6. PubMed ID: 21990410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
    Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
    J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
    Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
    Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
    Gulyas M; Mattsson JSM; Lindgren A; Ek L; Lamberg Lundström K; Behndig A; Holmberg E; Micke P; Bergman B;
    Acta Oncol; 2018 Feb; 57(2):244-250. PubMed ID: 29140138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
    Gadgeel SM; Wozniak A; Ruckdeschel JC; Heilbrun LK; Venkatramanamoorthy R; Chaplen RA; Kraut MJ; Kalemkerian GP
    J Thorac Oncol; 2008 Nov; 3(11):1293-300. PubMed ID: 18978565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
    Edelman MJ; Wang X; Hodgson L; Cheney RT; Baggstrom MQ; Thomas SP; Gajra A; Bertino E; Reckamp KL; Molina J; Schiller JH; Mitchell-Richards K; Friedman PN; Ritter J; Milne G; Hahn OM; Stinchcombe TE; Vokes EE;
    J Clin Oncol; 2017 Jul; 35(19):2184-2192. PubMed ID: 28489511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
    Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
    Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
    Nugent FW; Mertens WC; Graziano S; Levitan N; Collea R; Gajra A; Marshall J; McCann J
    Lung Cancer; 2005 May; 48(2):267-73. PubMed ID: 15829328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Agarwala A; Fisher W; Bruetman D; McClean J; Taber D; Titzer M; Juliar B; Yu M; Breen T; Einhorn LH; Hanna N
    J Thorac Oncol; 2008 Apr; 3(4):374-9. PubMed ID: 18379355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
    Fidias PM; Dakhil SR; Lyss AP; Loesch DM; Waterhouse DM; Bromund JL; Chen R; Hristova-Kazmierski M; Treat J; Obasaju CK; Marciniak M; Gill J; Schiller JH
    J Clin Oncol; 2009 Feb; 27(4):591-8. PubMed ID: 19075278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
    Altorki NK; Keresztes RS; Port JL; Libby DM; Korst RJ; Flieder DB; Ferrara CA; Yankelevitz DF; Subbaramaiah K; Pasmantier MW; Dannenberg AJ
    J Clin Oncol; 2003 Jul; 21(14):2645-50. PubMed ID: 12860939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
    Koch A; Bergman B; Holmberg E; Sederholm C; Ek L; Kosieradzki J; Lamberg K; Thaning L; Ydreborg SO; Sörenson S;
    Eur J Cancer; 2011 Jul; 47(10):1546-55. PubMed ID: 21565487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
    Gebbia V; Gridelli C; Verusio C; Frontini L; Aitini E; Daniele B; Gamucci T; Mancuso G; Di Maio M; Gallo C; Perrone F; Morabito A
    Lung Cancer; 2009 Feb; 63(2):251-8. PubMed ID: 18632181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
    Schneider BJ; Kalemkerian GP; Kraut MJ; Wozniak AJ; Worden FP; Smith DW; Chen W; Gadgeel SM
    J Thorac Oncol; 2008 Dec; 3(12):1454-9. PubMed ID: 19057272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
    Argiris A; Kut V; Luong L; Avram MJ
    Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.